Substituted pyrazolo piperidine carboxylic acids

ChangeBridge: Patent Grants - Organic Chemistry (C07D)

Published April 7th, 2026

Detected April 7th, 2026

Summary

USPTO granted patent US12595247B2 to Bayer Aktiengesellschaft covering substituted pyrazolo piperidine carboxylic acids, their salts, and processes for preparation. The patent includes 6 claims and lists 18 inventors. The compounds are directed toward cardiovascular and cardiac diseases, including heart failure with reduced, mid-range, and preserved ejection fraction.

View original document View source feed page

What changed

USPTO granted patent US12595247B2 for substituted pyrazolo piperidine carboxylic acids to Bayer Aktiengesellschaft. The patent covers compounds useful for treating cardiovascular diseases, heart failure, hypertension, peripheral arterial diseases, chronic kidney disease, pulmonary hypertension, neurodegenerative diseases, and fibrotic diseases. The patent includes 6 claims and was granted with kind B2.

Pharmaceutical companies developing cardiovascular or renal drugs should assess freedom-to-operate to avoid infringing Bayer's newly granted patent claims. Generic or biosimilar manufacturers may explore licensing opportunities. Researchers studying the specified disease areas should consider the newly granted patent rights when designing studies or developing competing compounds.

What to do next

Monitor for patent expiration dates and freedom-to-operate implications
Review product development pipeline for potential infringement of granted claims
Consider licensing opportunities for interested parties

Source document (simplified)

← USPTO Patent Grants

Substituted pyrazolo piperidine carboxylic acids

Grant US12595247B2 Kind: B2 Apr 07, 2026

Assignee

Bayer Aktiengesellschaft

Inventors

Alexandros Vakalopoulos, Marie-Pierre Collin-Kröpelin, Nuria Ortega Hernandez, Andre Dieskau, Melissa Boultadakis-Arapinis, Lisa Candish, Timo Stellfeld, Ilka Mathar, Lucas Hudson Hofmeister, Peter Sandner, Frank Wunder, Lisa Dietz, Robert Alan Webster, Carsten Schmeck, Thomas Mondritzki

Abstract

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).